Fulvested 250mg Injection

About

Fulvested 250mg Injection contains fulvestrant, an estrogen receptor antagonist used in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. It functions by selectively degrading the estrogen receptor, thereby blocking estrogen's ability to stimulate the growth of cancer cells. This unique mechanism of action distinguishes it from other endocrine therapies, as it leads to a downregulation of estrogen receptors.

By reducing the number of estrogen receptors within breast cancer cells, fulvestrant effectively inhibits the proliferative signals driven by estrogen. This makes it a valuable therapeutic option for patients whose tumors are dependent on estrogen for growth, particularly those who have progressed on other endocrine therapies like aromatase inhibitors.

Uses

• Treatment of hormone receptor-positive metastatic breast cancer
• Endocrine therapy for advanced breast cancer
• Management of breast cancer in postmenopausal women
• Used after progression on prior endocrine therapy

Directions For Use

Administer intramuscularly into the buttock by a healthcare professional, usually once a month. Do not self-inject.

Benefits

• Effective in hormone-sensitive breast cancer
• Alternative to aromatase inhibitors
• Can be used after progression on other endocrine therapies
• Well-tolerated with a manageable side effect profile
• Convenient monthly dosing regimen
• Non-oral administration for patients with compliance issues

Side Effects

• Injection site reactions (pain, inflammation)
• Nausea
• Fatigue
• Headache
• Hot flashes
• Arthralgia (joint pain)
• Back pain
• Vomiting
• Constipation
• Diarrhea
• Rash
• Peripheral edema

Safety Measures

• Alcohol - No direct interaction, but general health advice regarding alcohol consumption applies during cancer treatment.
• Pregnancy - Contraindicated; causes fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Contraindicated; unknown if excreted in milk, but potential for serious adverse effects in the infant.
• Liver - Use with caution in moderate to severe hepatic impairment; dose adjustment may be needed.
• Kidney - No dose adjustment needed for mild to moderate renal impairment; caution with severe impairment.
• Lung - No specific lung concerns, but monitor for general adverse effects and overall patient well-being.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.